Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Ito, Emiko  [Clear All Filters]
2014
Kawamura T, Miyagawa S, Fukushima S, Yoshida A, Kashiyama N, Kawamura A, Ito E, Saito A, Maeda A, Eguchi H, et al. N-Glycans: Phenotypic Homology and Structural Differences between Myocardial Cells and Induced Pluripotent Stem Cell-Derived Cardiomyocytes. PLoS One. 2014;9(10):e111064.
2018
Ishida M, Miyagawa S, Saito A, Fukushima S, Harada A, Ito E, Ohashi F, Watabe T, Hatazawa J, Matsuura K, et al. Transplantation of human induced pluripotent stem cell-derived cardiomyocytes is superior to somatic stem cell therapy for restoring cardiac function and oxygen consumption in a porcine model of myocardial infarction. Transplantation. 2018.
2019
Ohashi F, Miyagawa S, Yasuda S, Miura T, Kuroda T, Itoh M, Kawaji H, Ito E, Yoshida S, Saito A, et al. CXCL4/PF4 is a predictive biomarker of cardiac differentiation potential of human induced pluripotent stem cells. Sci Rep. 2019;9(1):4638.
2021
Takeda M, Ito E, Minami K, Harada A, Mochizuki-Oda N, Sawa Y, Miyagawa S. Elimination of residual undifferentiated induced pluripotent stem cells (iPSCs) using irradiation for safe clinical applications of iPSC-derived cardiomyocytes. Biochem Biophys Res Commun. 2021;574:91-96.
2022
Nakazato T, Kawamura T, Uemura T, Liu L, Li J, Sasai M, Harada A, Ito E, Iseoka H, Toda K, et al. Engineered three-dimensional cardiac tissues maturing in a rotating wall vessel bioreactor remodel diseased hearts in rats with myocardial infarction. Stem Cell Reports. 2022.
2023
Ito E, Kawamura A, Kawamura T, Takeda M, Harada A, Mochizuki-Oda N, Sawa Y, Miyagawa S. Establishment of a protocol to administer immunosuppressive drugs for iPS cell-derived cardiomyocyte patch transplantation in a rat myocardial infarction model. Sci Rep. 2023;13(1):10530.
Kawamura T, Ito Y, Ito E, Takeda M, Mikami T, Taguchi T, Mochizuki-Oda N, Sasai M, Shimamoto T, Nitta Y, et al. Safety confirmation of induced pluripotent stem cell-derived cardiomyocyte patch transplantation for ischemic cardiomyopathy: first three case reports. Front Cardiovasc Med. 2023;10:1182209.
2024
Hasegawa M, Miki K, Kawamura T, Sasozaki ITakei, Higashiyama Y, Tsuchida M, Kashino K, Taira M, Ito E, Takeda M, et al. Gene correction and overexpression of TNNI3 improve impaired relaxation in engineered heart tissue model of pediatric restrictive cardiomyopathy. Dev Growth Differ. 2024.